IT-IS International Sues Roche for Breach of Confidentiality, IP Infringement

Jan 08, 2014

|

NEW YORK (GenomeWeb News) — IT-IS International, a privately owned product development company specializing in the life sciences, has filed a pair of lawsuits in Germany against Roche for allegedly infringing intellectual property belonging to IT-IS and breaching a confidentiality disclosure agreement related to quantitative PCR technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

What You Might Learn

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

In the Skin

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

From Whales to Urchins to Algae

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

This Week in PNAS

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.

Featured White Papers

Discovering Neuronal Cell Types

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

FEMTO Pulse Genomic DNA Sizing and Quality Control

xMAP Cookbook: A collection of methods and protocols for developing multiplex assays with xMAP Technology

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Main menu